Publication Laka-library:
2017 Medical Isotope Supply Review: Mo/Tc Market Demand and Production Capacity Projection 2017-2022

AuthorOECD, NEA
6-07-4-60-29.pdf
DateApril 2017
Classification 6.07.4.60/29 (MISCELLANEOUS - NUCLEAR MEDICINE / MEDICAL APPLICATIONS - RADIO-ISOTOPES)
Remarks Available at OECD-NEA-site.

From the publication:

NEA/SEN/HLGMR(2017)2




                                     Chapter 1. Introduction



    Medical diagnostic imaging techniques using technetium-99m (99mTc) account for
    approximately 80% of all nuclear medicine procedures, representing 30-40 million
    examinations worldwide every year. Disruptions in the supply chain of these medical
    isotopes – which have half-lives of 66 hours for molybdenum-99 (99Mo) and only 6 hours
    for 99mTc, and thus must be produced continuously – can lead to cancellations or delays in
    important medical testing services. Supply reliability has been challenged over the past
    decade due to unexpected shutdowns and extended refurbishment periods at some of
    the 99Mo-producing research reactors and processing facilities. These shutdowns have at
    times created conditions for extended global supply shortages (e.g. 2009-2010).
        At the request of its member countries, the Nuclear Energy Agency (NEA) became
    involved in global efforts to ensure a secure supply of 99Mo/99mTc. Since June 2009, the
    NEA and its High-level Group on the Security of Supply of Medical Radioisotopes (HLG-MR)
    have examined the causes of supply shortages and developed a policy approach,
    including principles and supporting recommendations to address those causes. The NEA
    has reviewed the global 99Mo supply situation periodically, to highlight periods of
    potential reduced supply and to underscore the case for implementing the HLG-MR policy
    approach in a timely and globally consistent manner.
         In 2012, the NEA released a 99Mo supply and demand forecast up to 2030, identifying
    periods of potential low supply relative to demand. That 2012 forecast was updated with
    a report in 2014 that focused on the much shorter 2015-2020 period. That report was
    updated in 2015 and then in 2016 with a report, “2016 Medical Isotope Supply Review:
    99
       Mo/99mTc Market Demand and Production Capacity Projection 2016-2021” (NEA, 2016),
    which likewise focused on a six-year period.
         This report 1 updates the 2016 report, and focuses on the important 2017-2022 period
    that follows a period when some facilities have been removed from service. At the end of
    2015, the OSIRIS reactor in France permanently shut down operations. At the end of
    October 2016, the National Research Universal (NRU) reactor in Canada ceased routine
    99
       Mo production and the associated processing capacity moved to a “hot standby” mode;
    they retain the capability to provide contingency capacity until the end of March 2018,
    but only in exceptional circumstances of an unplanned global shortage that cannot
    otherwise be mitigated. Additional reactor capacity and associated processing capacity
    from existing supply chain members were added during 2016, but non-reactor-based
    99
       Mo/99mTc projects that were anticipated to start in 2016 have not yet entered operation.
    It remains important to analyse the likely overall impact and timing of anticipated
    projects to understand how global production capacity may be affected.
        This report presents global irradiation and processing capacity under the same three
    main capacity scenarios as set out in the 2015 and 2016 reports. It is intended that it
    offers a high added value to the international community and the HLG-MR has